{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:10:25Z","timestamp":1792509025035,"version":"4.5.0"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>Immune checkpoint inhibitors-induced pancreatitis (ICIs-P) is an uncommon immune-related adverse event. The available evidence consists mostly of case reports, case series, and narrative reviews. This research focuses on the clinical characteristics and management options for ICIs-P to provide a practice-based global perspective on this disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Five electronic databases were systematically reviewed to identify the relevant studies. Furthermore, we performed a disproportionality analysis utilizing OpenVigil 2.1 to interrogate the United States Food and Drug Administration\u2019s Adverse Event Reporting System (FAERS) database.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 61 patients from 58 studies were included in this study. Most patients with ICIs-P were males (60.7%). Most patients received anti-PD-1\/PD-L1 monotherapy (78.7%) or anti-PD-1\/PD-L1 monotherapy in conjunction with CTLA-4 blockade (19.7%). The median time from the initiation of immune checkpoint inhibitors treatment to pancreatitis was 108 days (range 52\u2013278). Most cases were severe or life-threatening (G3\u2013G4; 64.0%). Corticosteroids were administered to 73.8% of the patients during the treatment of pancreatitis. Regarding treatment outcomes, ICIs-P was reversible in most cases (83.6%), despite the 8.2% relapse and 8.2% deaths. We identified 606 reports of pancreatitis associated with ICIs in the FAERS database, with the greatest proportion of males (50.7%), 62.0% of PD-1 inhibitors, and 22.1% of all reports of death or life-threatening outcomes. Signals indicating pancreatitis were observed across all ICIs, with particular emphasis on Cemiplimab, Pembrolizumab and Nivolumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>By using a pharmacovigilance database, we discovered an elevated risk of pancreatitis following ICIs therapy, especially with PD-1 inhibitors. Meanwhile, risk factors for ICIs-P remain poorly understood, and diagnosis is challenging. Which may manifest as asymptomatic elevated pancreatic enzyme levels or clinical pancreatitis. Patients with pancreatitis symptoms should have their lipase and amylase levels and radiology evaluated. Diagnosis should be made by excluding other causes. Steroids are the cornerstone of ICIs-P treatment and slow dose reduction is recommended to reduce recurrence.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1426847","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T07:14:01Z","timestamp":1742368441000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Immune checkpoint inhibitors-induced pancreatitis: a systematic review and real-world pharmacovigilance analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Wei","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoran","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40425-019-0502-7","article-title":"Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury","volume":"7","author":"Abu-Sbeih","year":"","journal-title":"J. Immunother. Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s40425-019-0604-2","article-title":"Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment","volume":"7","author":"Abu-Sbeih","year":"","journal-title":"J. Immunother. Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s00261-019-01935-2","article-title":"Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor","volume":"44","author":"Alessandrino","year":"2019","journal-title":"Abdom. Radiol. (NY)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"A167","DOI":"10.1136\/ejhpharm-2020-eahpconf.356","article-title":"Pancreatitis induced by immunotherapy? Two case reports","volume":"27","author":"Bachiller","year":"2020","journal-title":"Eur. J. Hosp. Pharm."},{"key":"B4","doi-asserted-by":"publisher","first-page":"720776","DOI":"10.3389\/fphar.2021.720776","article-title":"Common immune-related adverse events of immune checkpoint inhibitors in the gastrointestinal system: a study based on the us Food and drug administration adverse event reporting system","volume":"12","author":"Bai","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ejca.2020.01.013","article-title":"Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies","volume":"129","author":"Baldini","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ejca.2018.02.006","article-title":"Focal immune-related pancreatitis occurring after treatment with programmed cell death 1 inhibitors: a distinct form of autoimmune pancreatitis?","volume":"95","author":"Capurso","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1136\/jim-2021-MW.36","article-title":"A rare case of asymptomatic pancreatitis due to atezolizumab, an immune checkpoint inhibitor","volume":"69","author":"Chandler","year":"2021","journal-title":"J. Investigative Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"S891","DOI":"10.1016\/s0016-5085(17)33042-1","article-title":"First reported case of pembrolizumab-induced immune mediated hemorrhagic gastritis","volume":"152","author":"Cinnor","year":"2017","journal-title":"Gastroenterology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S1470-2045(18)30261-4","article-title":"Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis","volume":"19","author":"Conforti","year":"2018","journal-title":"Lancet Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1097\/RLU.0000000000002692","article-title":"Focal immunotherapy-induced pancreatitis mimicking metastasis on FDG PET\/CT","volume":"44","author":"Das","year":"2019","journal-title":"Clin. Nucl. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"109250","DOI":"10.1016\/j.ejrad.2020.109250","article-title":"Imaging findings of immune checkpoint inhibitor associated pancreatitis","volume":"131","author":"Das","year":"2020","journal-title":"Eur. J. Radiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1530\/EJE-19-0291","article-title":"Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review","volume":"181","author":"de Filette","year":"2019","journal-title":"Eur. J. Endocrinol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ejca.2018.09.014","article-title":"Autoimmune pancreatitis after nivolumab anti-programmed death receptor-1 treatment","volume":"104","author":"Dehghani","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1243773","DOI":"10.3389\/fimmu.2023.1243773","article-title":"Immune checkpoint inhibitors-related pancreatitis with fulminant type 1 diabetes mellitus: case report and literature review","volume":"14","author":"Fang","year":"2023","journal-title":"Front. Immunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr. Engl. Ed."},{"key":"B19","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.pan.2019.04.015","article-title":"Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: a systematic review and meta-analysis","volume":"19","author":"George","year":"2019","journal-title":"Pancreatology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"100042","DOI":"10.1016\/j.esmoop.2020.100042","article-title":"A prospective cohort study on the safety of checkpoint inhibitors in older cancer patients - the ELDERS study","volume":"6","author":"Gomes","year":"2021","journal-title":"ESMO Open"},{"key":"B21","doi-asserted-by":"publisher","first-page":"S740","DOI":"10.14309\/01.ajg.0000707884.05320.32","article-title":"Immune checkpoint inhibitor-induced pancreatic injury: an atypical presentation","volume":"115","author":"Goyal","year":"2020","journal-title":"Am. J. Gastroenterology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1200\/EDBK_100013","article-title":"Gastrointestinal and hepatic toxicities of checkpoint inhibitors: algorithms for management","volume":"38","author":"Grover","year":"2018","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1461398","DOI":"10.3389\/fphar.2024.1461398","article-title":"Association between different GLP-1 receptor agonists and acute pancreatitis: case series and real-world pharmacovigilance analysis","volume":"15","author":"Guo","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"iv264","DOI":"10.1093\/annonc\/mdy162","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Haanen","year":"2018","journal-title":"Ann. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e00667","DOI":"10.14309\/ctg.0000000000000667","article-title":"Incidence of pancreatic injury and pancreatitis in patients treated with immune checkpoint inhibitors","volume":"15","author":"Hori","year":"2024","journal-title":"Clin. Transl. Gastroenterol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.lungcan.2016.07.001","article-title":"Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: a case report","volume":"99","author":"Ikeuchi","year":"2016","journal-title":"Lung Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1097\/MPA.0000000000001107","article-title":"Anti-PD-1 drug (nivolumab) may induce acute and life-threatening pancreatitis in lung cancer patient: a case report","volume":"47","author":"Jiang","year":"2018","journal-title":"Pancreas"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1093\/jnci\/djab035","article-title":"Association between sex and immune-related adverse events during immune checkpoint inhibitor therapy","volume":"113","author":"Jing","year":"2021","journal-title":"J. Natl. Cancer Inst."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e00525","DOI":"10.1002\/rcr2.525","article-title":"Pembrolizumab-related pancreatitis with elevation of pancreatic tumour markers","volume":"8","author":"Kakuwa","year":"2020","journal-title":"Respirol. Case Rep."},{"key":"B30","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1097\/CMR.0000000000000611","article-title":"Immune-related pancreatitis associated with checkpoint blockade in melanoma","volume":"29","author":"Kohlmann","year":"2019","journal-title":"Melanoma Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/CJI.0000000000000472","article-title":"Immune checkpoint inhibitor-related pancreatitis: a case series, review of the literature and an expert opinion","volume":"46","author":"Kramer","year":"2023","journal-title":"J. Immunother."},{"key":"B32","doi-asserted-by":"publisher","first-page":"627612","DOI":"10.3389\/fonc.2021.627612","article-title":"Immunotherapy-associated pancreatic adverse events: current understanding of their mechanism, diagnosis, and management","volume":"11","author":"Liu","year":"2021","journal-title":"Front. Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"663088","DOI":"10.3389\/fphar.2021.663088","article-title":"Pericardial toxicities associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database","volume":"12","author":"Ma","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/CJI.0000000000000202","article-title":"Significance of immune-related lipase increase induced by antiprogrammed death-1 or death ligand-1 antibodies: a brief communication","volume":"41","author":"Michot","year":"2018","journal-title":"J. Immunother."},{"key":"B35","doi-asserted-by":"publisher","first-page":"bbab347","DOI":"10.1093\/bib\/bbab347","article-title":"Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source","volume":"22","author":"Noguchi","year":"2021","journal-title":"Brief. Bioinform"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.3390\/cancers13051131","article-title":"Adverse event reporting with immune checkpoint inhibitors in older patients: age subgroup disproportionality analysis in VigiBase","volume":"13","author":"Noseda","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e68043","DOI":"10.7759\/cureus.68043","article-title":"Immune checkpoint inhibitors in cancer treatment and incidence of pancreatitis","volume":"16","author":"Nwankwo","year":"2024","journal-title":"Cureus"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1007\/s12328-021-01499-z","article-title":"Pembrolizumab-induced autoimmune side effects of colon and pancreas in a patient with lung cancer","volume":"14","author":"Ofuji","year":"2021","journal-title":"Clin. J. GASTROENTEROLOGY"},{"key":"B39","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.autrev.2014.01.010","article-title":"Diagnosis and classification of autoimmune pancreatitis","volume":"13","author":"Okazaki","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"B40","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.3390\/curroncol28050283","article-title":"Safety of immune checkpoint inhibitors in elderly patients: an observational study","volume":"28","author":"Paderi","year":"2021","journal-title":"Curr. Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"S763","DOI":"10.14309\/01.ajg.0000595044.94402.db","article-title":"1379\u2003Immune checkpoint inhibitor-induced acute pancreatitis and colitis","volume":"114","author":"Pagan","year":"2019","journal-title":"Am. J. Gastroenterology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"J109","DOI":"10.1016\/j.jaut.2011.10.003","article-title":"Autoimmune disease and gender: plausible mechanisms for the female predominance of autoimmunity","volume":"38","author":"Quintero","year":"2012","journal-title":"J. Autoimmun."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1053\/j.gastro.2020.06.093","article-title":"Insights from pharmacovigilance: gastrointestinal-related immune checkpoint inhibitor adverse events","volume":"159","author":"Reese","year":"2020","journal-title":"Gastroenterology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1148\/radiol.2019191603","article-title":"Nivolumab-induced pancreatitis: an immune-related adverse event","volume":"293","author":"Saito","year":"2019","journal-title":"Radiology"},{"key":"B46","doi-asserted-by":"publisher","first-page":"791","DOI":"10.2169\/internalmedicine.1943-23","article-title":"Immune checkpoint inhibitor-induced pancreatitis with pancreatic enlargement mimicking autoimmune pancreatitis: a case report and review of the literature","volume":"63","author":"Sakaguchi","year":"2024","journal-title":"Intern Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1158\/2326-6066.CIR-17-0755","article-title":"Safety and efficacy of Re-treating with immunotherapy after immune-related adverse events in patients with NSCLC","volume":"6","author":"Santini","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1097\/MOG.0000000000000873","article-title":"Type 3 autoimmune pancreatitis (immune checkpoint inhibitor-induced pancreatitis)","volume":"38","author":"Sayed","year":"2022","journal-title":"Curr. Opin. Gastroenterol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1200\/JCO.2017.73.2289","article-title":"Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials","volume":"35","author":"Schadendorf","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1097\/MPA.0b013e3182142fd2","article-title":"International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology","volume":"40","author":"Shimosegawa","year":"2011","journal-title":"Pancreas"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1027323","DOI":"10.1155\/2018\/1027323","article-title":"Risk of immune-related pancreatitis in patients with solid tumors treated with immune checkpoint inhibitors: systematic assessment with meta-analysis","volume":"2018","author":"Su","year":"2018","journal-title":"J. Immunol. Res."},{"key":"B52","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ctrv.2017.06.002","article-title":"Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management","volume":"58","author":"Sznol","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"B53","doi-asserted-by":"publisher","first-page":"791","DOI":"10.2169\/internalmedicine.1943-23","article-title":"Immune checkpoint inhibitor-induced pancreatitis with pancreatic enlargement mimicking autoimmune pancreatitis: a case report and review of the literature","volume":"63","author":"Tanabe","year":"2024","journal-title":"Intern Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.pan.2020.11.002","article-title":"An autopsy case of severe acute pancreatitis induced by administration of pazopanib following nivolumab","volume":"21","author":"Tanaka","year":"2021","journal-title":"Pancreatology"},{"key":"B55","doi-asserted-by":"publisher","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","article-title":"Management of immunotherapy-related toxicities, version 1.2019","volume":"17","author":"Thompson","year":"2019","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"B56","doi-asserted-by":"publisher","first-page":"S740","DOI":"10.14309\/01.ajg.0000780144.09245.72","article-title":"S1653\u2003Infliximab for steroid-refractory immune checkpoint inhibitor-induced pancreatitis","volume":"116","author":"Townsend","year":"2021","journal-title":"Am. J. Gastroenterology"},{"key":"B57","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.jemermed.2018.08.009","article-title":"Acute pancreatitis: updates for emergency clinicians","volume":"55","author":"Waller","year":"2018","journal-title":"J. Emerg. Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1186\/s12885-024-13284-5","article-title":"Evaluate the renal system damage caused by zoledronic acid: a comprehensive analysis of adverse events from FAERS","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Cancer"},{"key":"B59","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"25712","DOI":"10.1038\/s41598-024-77889-3","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system events for Lutetium-177-PSMA-617","volume":"14","author":"Wu","year":"2024","journal-title":"Sci. Rep."},{"key":"B61","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/24725625.2021.1899444","article-title":"Acute pancreatitis without abdominal pain induced by administration of nivolumab and ipilimumab","volume":"5","author":"Yamamoto","year":"2021","journal-title":"Mod. Rheumatol. Case Rep."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.2169\/internalmedicine.7911-21","article-title":"The simultaneous onset of pancreatitis and colitis as immune-related adverse events in a patient receiving nivolumab treatment for renal cell carcinoma","volume":"61","author":"Yazaki","year":"2022","journal-title":"Intern Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1177\/10781552211028636","article-title":"Two different immune related adverse events occured at pancreas after nivolumab in an advanced RCC patient","volume":"28","author":"Yilmaz","year":"2022","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B64","doi-asserted-by":"publisher","first-page":"357","DOI":"10.5009\/gnl210241","article-title":"Type 2 autoimmune pancreatitis: consensus and controversies","volume":"16","author":"Zen","year":"2022","journal-title":"Gut Liver"},{"key":"B65","doi-asserted-by":"publisher","first-page":"817662","DOI":"10.3389\/fphar.2022.817662","article-title":"Pancreatic adverse events associated with immune checkpoint inhibitors: a large-scale pharmacovigilance analysis","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1426847\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T07:14:05Z","timestamp":1742368445000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1426847\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":65,"alternative-id":["10.3389\/fphar.2025.1426847"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1426847","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,19]]},"article-number":"1426847"}}